Position in INBX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$29,219,478
+$8,685,352 QoQ
Shares Held
308,385
+1.0% QoQ
Ownership
2.10%
of shares outstanding
% of Portfolio
2.54%
of 13F equity value
Holder Rank
#14
of 161 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in INBX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026PFM Health Sciences, LP holds $494,895,363 across 45 Biotechnology names. INBX ranks #4 (5.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
233,171 | $62,191,369 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
219,596 | $53,750,512 | |
| 3 | JAZZ |
Jazz Pharmaceuticals plc
|
160,768 | $38,740,264 | |
| 4 | INBX |
Inhibrx Biosciences, Inc.
This page
|
308,385 | $29,219,478 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
143,222 | $26,822,616 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
253,358 | $18,870,103 | |
| 7 | CYTK |
Cytokinetics Inc
|
191,686 | $16,329,730 | |
| 8 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
29,313 | $15,739,615 |
All Filings in INBX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29,219,478 | 308,385 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $20,534,126 | 305,431 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $20,975,843 | 265,517 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $8,071,209 | 239,644 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $3,485,604 | 244,261 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $6,145,569 | 439,283 | Shares | Defined | 2025-05-15 | |
| 2024-12-31 | $2,087,408 | 135,546 | Shares | Defined | 2025-02-14 | |
| 2024-09-30 | $2,122,650 | 135,546 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $1,920,686 | 135,546 | Shares | Defined | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||